BACKGROUND: Given the rising incidence of endometrial cancer in Saudi Arabia, the integration of high-cost therapeutics, such as dostarlimab (DSR), for primary advanced or recurrent (pA/rEC) disease necessitates rigorous economic appraisal. Therefore, this study aimed to evaluate the cost-utility of first-line dostarlimab plus carboplatin-paclitaxel (DSR + CP) versus placebo plus carboplatin-paclitaxel (PBO + CP) from the perspective of the Saudi healthcare payer. METHODS: A partitioned survival model was constructed to simulate patient prognosis across three health states: progression-free disease, progressive disease, and death. The model parameters were derived from the clinical efficacy data of the RUBY trial and the local cost inputs. The primary outcome was the incremental cost-effectiveness ratio (ICER), the robustness of which was evaluated via comprehensive deterministic and probabilistic sensitivity analyses to characterize parameter uncertainty. RESULTS: For the overall pA/rEC population, the DSR + CP regimen yielded an incremental 1.55 quality-adjusted life-years (QALYs) at an additional cost of $144,716, resulting in an ICER of $93,244 per QALY. Cost-effectiveness was more favorable in the mismatch repair deficient (dMMR) subgroup (ICER: $82,754/QALY) than in the mismatch repair proficient (pMMR) cohort (ICER: $132,571/QALY). The ICER is the most sensitive to the acquisition cost of the DSR. At a willingness-to-pay threshold of $90,000/QALY, the probability of DSR + CP being cost-effective was 83.9% for the dMMR subgroup. CONCLUSION: This economic evaluation indicates that DSR + CP constitutes a cost-effective intervention for pA/rEC within the dMMR subpopulation. These findings provide strong evidence for a tailored reimbursement policy that effectively utilizes resources by connecting clinical benefits with economic value in the management of pA/rEC.
INQUIRY The Journal of Health Care Organization Provision and Financing · مجلد 63 · 469580251405998-469580251405998
Teledermatology has become an important tool for expanding access to dermatologic care, especially in geographically large countries such as Saudi Arabia. Saudi Arabia's digital transformation and the shortage of dermatologists in rural regions have created favorable conditions for the adoption of teledermatology. Several platforms now provide virtual dermatology consultations. This narrative review aimed to explore teledermatology's current status, acceptance, barriers, and future directions in Saudi Arabia. The literature indicates that both dermatologists and patients are generally receptive to teledermatology, particularly for follow-up care; however, concerns about the lack of physical examination and reduced interpersonal interaction persist. A SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis revealed that Saudi Arabia's strong digital infrastructure, high smartphone penetration, and alignment with Vision 2030 are major strengths supporting teledermatology expansion. Key weaknesses include regulatory and reimbursement gaps, limited digital literacy, and the lack of dermatology-specific guidelines. Opportunities lie in extending services to underserved areas and integrating artificial intelligence, whereas threats include cultural resistance, cybersecurity risks, and potential inequities in digital access. In conclusion, teledermatology in Saudi Arabia is rapidly developing and shows considerable promise; however, its sustainability will depend on targeted investment, regulatory reforms, and efforts to promote equitable access.
teledermatologySaudi Arabiaaccess to dermatologic caretelehealth adoption barriers
Telehealth adoption gained popularity during the coronavirus disease 2019 (COVID-19) pandemic and had substantial and various impacts on patient outcomes depending on the specific environment, healthcare system, and quality of telehealth services supplied. Hence, this systematic review explored those impacts and their sustainability post-pandemic. To conduct this systematic review, a thorough literature search was undertaken in electronic databases such as PubMed, Medline, Web of Science, Google Scholar, databases, Embase, and PsycINFO using relevant keywords. We included articles written in English and published in the last 10 years that reported on the impact of telehealth adoption on various patient outcomes and the impact of sustainability post-pandemic. The findings of this systematic review highlight the remarkable impact of telehealth adoption on patient outcomes and the sustainability of these initiatives post-pandemic. Telehealth has proven to enhance various aspects of healthcare, spanning from prevention to follow-up. Another effect of telehealth adoption is the significant reduction in hospitalizations. Furthermore, telehealth profoundly impacts hospital stays, leading to a decrease in all-cause hospital days per patient by 1.07 (95% confidence interval (CI): 1.76 to 0.39) days and a shorter mean hospital stay for condition-related hospitalizations by 89% (95% CI 1.42 to 0.36), providing evidence of efficient healthcare delivery. There was also a reduction in mortality rates for patients receiving telemedicine interventions. Telehealth is also cost-effective while remaining highly effective. Patient satisfaction is another key outcome of telehealth adoption observed. The convenience and reduced expenses of telehealth have garnered positive feedback from patients, reinforcing the desirability of telehealth as a viable alternative to in-person visits. Despite these numerous benefits, barriers and disparities in telehealth adoption and utilization persist, especially in rural hospitals that face challenges, including a lack of Health Information Exchange (HIE) capacity, limited patient engagement capabilities, and the absence of financial reimbursement. This systematic review underscores the remarkable impact of telehealth adoption on patient outcomes and its sustainability post-pandemic. However, barriers and disparities still exist, requiring attention to ensure equitable access to telehealth services. The evidence supports the continued development and implementation of telehealth initiatives to improve healthcare delivery and patient outcomes post-pandemic.
Frontiers in Pharmacology · مجلد 16 · 1695961-1695961
Background: Cell and gene therapies (CGTs) challenge traditional Health Technology Assessment (HTA), creating a fragmented global access landscape. This study identifies the determinants of CGT reimbursement outcomes by quantifying the influence of key variables and identifying the configurations leading to a positive recommendation. Methods: A dual-methodology approach was employed. We constructed a comprehensive dataset of all HTA decisions for CGTs across seven major jurisdictions between January 2017 and July 2025. Hierarchical Linear Modeling (HLM) was used to identify independent predictors of HTA outcomes, and Fuzzy-Set Qualitative Comparative Analysis (fsQCA) was used to identify sufficient pathways to success. Novel composite indicators were developed to measure system-level adaptability and the influence of patient advocacy groups (PAGs). Results: The HLM analysis, accounting for data clustering (Intraclass Correlation Coefficients (ICCs): 42% country-level, 24% agency-level variance), confirmed that strong clinical efficacy (Coef. = 0.40), high unmet need, and disease rarity were significant positive predictors. High therapy cost was a powerful negative predictor (Coef. = -0.29 per $1M USD). Crucially, high System Adaptability (Coef. = 0.35) and strong PAG Influence (Coef. = 0.28) emerged as major positive determinants. The fsQCA revealed three distinct pathways to a positive recommendation with high consistency: a "Transformative Value" path (consistency: 0.93), a "Strategic Mitigation" path (consistency: 0.90), and an "Economic Dominance" path (consistency: 0.94). The overall QCA solution explained a majority of positive outcomes (solution coverage: 0.68). Conclusion: HTA success for CGTs is not determined by isolated attributes but by the strategic alignment of therapy-level evidence, agency-level processes, and country-level context. The influence of organized patient advocacy and the structural flexibility of HTA systems are critical, previously under-quantified components of this alignment.
cell and gene therapyhealth technology assessmentreimbursement decisionspatient associations
Malaysian Journal of Pharmacy · مجلد 8 (1) · 42-56
The current study aims to explore the number of registered anticancer medicine in Pakistan and the price variation of these single-ingredient medicines. A data-based study was conducted between March 2021 and May 2021. Pharmaguide (Mobile Version 2020 – 2021), Druginfosys.com and Medicialstore.com.pk were used to derive the price of anticancer medications sold in Pakistan. The difference in minimum and maximum costs of each formulation was calculated, and the price variations in 81 anticancer medicines belonging to 14 different categories were analysed. There were 115 formulations registered for these 81 anticancer medications. Estimations in price difference revealed that topotecan (4mg / ml) had the highest price variation, while the lowest price variation of 4.01% was observed for abiraterone acetate (250mg). Price variations among different anti-cancer brands marketed in Pakistan are noticeable and substantial, therefore necessitating action from the drug regulatory authority of Pakistan, not only to gain awareness on this issue, but also to set pricing thresholds to make the prices of anti-cancer medications more affordable. In addition, external reference pricing and reimbursement programs partially sponsored by the government or insurance companies can be a possible way to control the price variation of anti-cancer drugs.
Academy of Management Proceedings · مجلد 2019 (1) · 11608-11608
The U.S. model for trauma care has been seen as one of the most advanced systems in the world, however, there are clear racial and ethnic disparities in the trauma care service delivery that warrant further investigation. Previous inquiry has indicated that the prevalence of trauma centers (TCs) may be related to environmental factors, and differences in health utilization. However, previous inquiry has not examined the possible relationships between structural determinants that relate to the level of trauma care designations (L-I through L-IV) or verification along with social factors of the surrounding community as it relates to its population of diversity. Thus, this study is focused on examining the relationship between community diversity in a Hospital Referral Region (HRR), and U.S.-based hospitals’ attainment of trauma certification and trauma designation L-I/II. We conducted a cross-sectional analysis of data from the 2017 American Hospital Association (AHA) Annual Survey, Current Population Survey (CPS) , and the Dartmouth Atlas Hospital Referral Region datasets. Poisson regression and propensity score matching were used to analyze 303 HRRs. Our primary dependent variables were hospitals with trauma certification and hospitals with trauma L-I/II. Our primary independent variable was the diversity of an HRR operationalized by estimating an entropy index score for each county–aggregated to the HRR level–that is comprised of the proportions of the ethnic groups. We found that hospitals with trauma certification or trauma L-I/II were more likely to be in HRRs with less diverse population. Furthermore, market competition was a significant factor in reducing the availability of trauma certified centers. Our findings highlight that in the U.S. system disparities do exist in trauma care. Research is needed to determine if other factors such as resource allocation and reimbursements distribution from Medicaid Disproportionate Share Hospital have impact the availability of trauma facilities.
trauma centershospital referral regionsracial and ethnic disparitiescommunity diversity